Jane Garland, a psychiatrist, clinical researcher and past investigator in SSRI trials, states that negative results from SSRI trials go unpublished, while the published evidence to support their use is flimsy at best. She calls on physician–researchers to take a collective stand and demand disclosure of all data.
In a related commentary, Herxheimer and Mintzes point to flawed trial design, secrecy in the approvals process and inadequate systems for adverse drug reporting as the mechanisms by which ineffective and unsafe drugs gain a place in the market.
p. 487 Antidepressants and adverse effects in young patients: uncovering the evidence -- A. Herxheimer, B. Mintzes
p. 489 Facing the evidence: antidepressant treatment in children and adolescents -- E.J. Garland
Canadian Medical Association Journal